Daiichi Sankyo Company, Limited: ENHERTU Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca s
ENHERTU (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210115005582/en/
ENHERTU (fam-trastuzumab deruxtecan-nxki) Vials on Conveyor Belt PP-US-EN-0383 2021 Daiichi Sankyo, Inc. AstraZeneca
In the U.S., gastric cancer is more frequently diagnosed in the advanced stage, with only approximately 5% of patients surviving five years.
Research and Markets: EU5 Bariatric Surgery Procedures Outlook to 2025 - Roux-en-Y Gastric Bypass (RYGB) Procedures, Sleeve Gastrectomy Procedures and Others - ResearchAndMarkets.com
ResearchAndMarkets.com s offering. EU5 Bariatric Surgery Procedures Outlook to 2025 is a comprehensive databook report, covering key procedures data on the EU5 Bariatric Surgery Procedures. The databook report provides procedure volumes within segments Gastric Balloon Procedures, Gastric Banding Procedures, Other Bariatric Surgeries, Roux-en-Y Gastric Bypass (RYGB) Procedures, Sleeve Gastrectomy Procedures.
The EU5 Bariatric Surgery Procedures report provides key information and data on
Procedure volume data for Bariatric Surgery Procedures related to the country. Data is provided from 2015 to 2025.
After defining extensive cellular heterogeneity, researchers from The University of Texas MD Anderson Cancer Center developed a tool that might be useful in str